Home / Jamjoom Pharmaceuticals Factory Co. / 2022 Annual Results

Jamjoom Pharmaceuticals Factory Co. 2022 Annual Results

Revenue

SAR 323M

Net Profit

SAR 171M

Jamjoom Pharmaceuticals Factory Co. (4015) reported full year 2022 revenue of SAR 323M, up 23.7% from SAR 261M in 2021. Net profit came in at SAR 171M, up 0.4% year on year. All figures sourced from CMA-mandated XBRL filings on the Saudi Exchange, processed by Sahm Screener.

Key Financial Metrics

Metric	2022	2021
Revenue	SAR 323M	SAR 261M
Net Profit	SAR 171M	SAR 171M
Gross Profit	SAR 594M	SAR 475M
Net Margin	53.1%	65.4%
ROE	14.1%	13.9%
Total Assets	SAR 1.41B	SAR 1.43B
Total Equity	SAR 1.22B	SAR 1.23B

Year on Year Comparison

Revenue increased by 23.7% compared to 2021. Net profit increased by 0.4%. Both revenue and profit grew — indicating expanding business.

View full company profile →

View all years:

2025 2024 2023 2022 2021 2020 2019

Financial data sourced from CMA-mandated XBRL filings published on the Saudi Exchange (Tadawul). Data processed and structured by Sahm Screener (sahmscreener.com). Updated nightly. Last updated: 2023-06-21.